AR032629A1 - COMPOUNDS DERIVED FROM IMIDAZOL AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM - Google Patents

COMPOUNDS DERIVED FROM IMIDAZOL AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM

Info

Publication number
AR032629A1
AR032629A1 ARP010103637A ARP010103637A AR032629A1 AR 032629 A1 AR032629 A1 AR 032629A1 AR P010103637 A ARP010103637 A AR P010103637A AR P010103637 A ARP010103637 A AR P010103637A AR 032629 A1 AR032629 A1 AR 032629A1
Authority
AR
Argentina
Prior art keywords
straight
branched chain
membered
nr7r8
independently selected
Prior art date
Application number
ARP010103637A
Other languages
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR032629A1 publication Critical patent/AR032629A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)

Abstract

Un compuesto por ser de formula (1) en la que: R1 es alquilo C1-8 de cadena lineal o ramificada, alquenilo C2-8 de cadena lineal o ramificada, alquinilo C2-8 de cadena lineal o ramificada, cicloalquilo C3-8, cicloalquenilo C4-8, heterocicloalquilo de 3-8 miembros, bicicloalquilo C5-11, bicicloalquenilo C7-11, heterobicicloalquilo de 5-11 miembros, arilo C6-14, o heteroarilo de 5-14 miembros; y estando R1 opcionalmente sustituido con 1-6 sustituyentes R5 seleccionados independientemente entre F, Cl, Br, I, nitro, ciano, -CF3, -NR7R8, -NR7C(=O)R8, -NR7C(=O)OR8, -NR7C(=O)NR8R, -NR7S(=O)2R8, -NR7S(=O)2R8R9, -OR7, -OC(=O)R7, -OC(=O)OR7, -C(=O)OR7, -C(=O)R7, -C(=O)NR7R8, -OC(=O)NR7R8, -OC(=O)SR7, -SR7, -S(=O)R7, -S(=O)2R7, -S(=O)2NR7R8, -O-S(=O)2R7, N3 y R7; R2 es H, F, -CH3, -CN o -C(=O)OR7; R3 es -C(=O)NR9, -C(=O)O-, -C(=O)(CR10R11)n-, o -(CR10R11)n-; R4 es alquilo C1-8 de cadena lineal o ramificada, alquenilo C2-8 de cadena lineal o ramificada, alquinilo C2-8 de cadena lineal o ramificada, cicloalquilo C3-8, cicloalquenilo C4-8, heterocicloalquilo de 3-8 miembros, bicicloalquilo C5-11, bicicloalquenilo C7-11, heterobicicloalquilo de 5-11 miembros, arilo C6-14 o heteroarilo de 5-14 miembros, estando R4 opcionalmente sustituido con 1-3 sustituyentes R6 seleccionados independientemente entre F, Cl, Br, I, nitro, ciano, -CF3, -NR7R8, -NR7C(=O)R8, -NR7C(=O)OR8, -NR7C(=O)NR8R9, -NR7S(=O)2R8, -NR7S(=O)2NR8R9, -OR7, -OC(=O)R7, -OC(=O)OR7, -C(=O)OR7, -C(=O)R7, -C(=O)NR7R8, -OC(=O)NR7R8, -OC(=O)SR7, -SR7, -S(=O)R7, -S(=O)2R7, -S(=O)2NR7R8, o R7; cada uno de R7, R8 y R9 se selecciona independientemente entre H, alquilo C1-8 de cadena lineal o ramificada, alquenilo C2-8 de cadena lineal o ramificada, alquinilo C2-8 de cadena lineal o ramificada, cicloalquilo C3-8, cicloalquenilo C4-8, heterocicloalquilo de 3-8 miembros, bicicloalquilo C5-11, bicicloalquenilo C7-11, heterobicicloalquilo de 5-11 miembros, arilo C6-14 y heteroarilo de 5-14 miembros, estando cada uno de R7, R8 y R9 opcional e independientemente sustituido con 1-6 sustituyentes seleccionados entre F, Cl, Br, I, NO2, -CN, -CF3, -NR10R11, -NR10C(=O)R11, -NR10C(=O)OR11, -NR10C(=O)NR11R12, -NR10S(=O)2R11, -NR10S(=O)2NR11R12, -OR10, -OC(=O)R10, -OC(=O)OR10, -OC(=O)NR10R11, -OC(=O)SR10, -SR10, -S(=O)R10, -S(=O)2R10, -S(=O)2NR10R11, -C(=O)R10, -C(=O)OR10, -C(=O)NR10R11 y R10; o, cuando R7 y R8 son como en NR7R8, pueden estar unidos opcionalmente para formar, junto con el nitrogeno de NR7R8 al que están unidos, un resto heterocicloalquilo de 3-7 miembros de anillo, comprendiendo opcionalmente dicho resto heterocicloalquilo 1-2 heteroátomos adicionales seleccionados independientemente entre N, O y S; cada uno de R10, R11 y R12 se selecciona independientemente entre H, alquilo C1-8 de cadena lineal o ramificada, alquenilo C2-8 de cadena lineal o ramificada, alquinilo C2-8 de cadena lineal o ramificada, cicloalquilo C3-8, cicloalquenilo C4-8, heterocicloalquilo de 3-8 miembros, bicicloalquilo C5-11, bicicloalquenilo C7-11, heterobicicloalquilo de 5-11 miembros, arilo C6-14 y heteroarilo de 5-14 miembros, estando cada uno de R10, R11 y R12 opcional e independientemente sustituido con 1-6 sustituyentes seleccionados entre F, Cl, Br, I, NO2, -CN, -CF3, -NR13R14, -NR13C(=O)R14, -NR13C(=O)OR14, -NR13C(=O)NR14R15, -NR13S(=O)2R14, -NR13S(=O)2NR14R15, -OR13, -OC(=O)R13, -OC(=O)OR13, -OC(=O)NR13R14, -OC(=O)SR13, -SR13, -S(=O)R13, -S(=O)2R13, -S(=O)2NR13R14, -C(=O)R13, -C(=O)OR13, -C(=O)NR13R14 y R13; cada uno de R13, R14 y R15 se selecciona independientemente entre H, alquilo C1-8 de cadena lineal o ramificada, alquenilo C2-8 de cadena lineal o ramificada, alquinilo C2-8 de cadena lineal o ramificada, cicloalquilo C3-8, cicloalquenilo C4-8, heterocicloalquilo de 3-8 miembros, bicicloalquilo C5-11, bicicloalquenilo C7-11, heterobicicloalquilo de 5-11 miembros, arilo C6-14 y heteroarilo de 5-14 miembros, estando cada uno de R13, R14 y R15 opcional e independientemente sustituido con 1-6 sustituyentes seleccionados entre F, Cl, Br, I, NO2, -CN, -CF3, -NR16R17, -NR16C(=O)R17, -NR16C(=O)OR17, -NR16C(=O)NR17R18, -NR16S(=O)2R17, -NR16S(=O)2NR17R18, -OR16, -OC(=O)R16, -OC(=O)OR16, -OC(=O)NR16R17, -OC(=O)SR16, -SR16, -S(=O)R16, -S(=O)2R16, -S(=O)2NR16R17, -C(=O)R16, -C(=O)OR16, -C(=O)NR16R17 y R16; cada uno de R16, R17 y R18 se selecciona independientemente entre H, alquilo C1-8 de cadena lineal o ramificada, alquenilo C2-8 de cadena lineal o ramificada, alquinilo C2-8 de cadena lineal o ramificada, cicloalquilo C3-8, cicloalquenilo C4-8, heterocicloalquilo de 3-8 miembros, bicicloalquilo C5-11, bicicloalquenilo C7-11, heterobicicloalquilo de 5-11 miembros, arilo C6-13 y heteroarilo de 5-12 miembros; n es 0, 1, 2 o 3; siendo R10 y R11 en -C(=O)(CR10R11)n- y -(CR10R11)n-, para cada repeticion de n, independientemente como se ha mencionado anteriormente; o una sal farmacéuticamente aceptable del mismo. Se indica que los compuestos de formula (1) tienen actividad inhibidora de cdk5, cdk2 y GSK-3. También se describen composiciones farmacéuticas y procedimientos que comprenden compuestos de formula (1) para tratar y prevenir enfermedades y afecciones que comprenden un crecimiento celular anormal, tal como el cáncer, enfermedades y afecciones neurodegenerativas, y las afectadas por la neurotransmision de dopamina. También se describen composiciones farmacéuticas y procedimientos que comprenden compuestos de formula (1) para tratar la fertilidad masculina y motilidad de los espermatozoides; diabetes mellitus; disminucion de la tolerancia a la glucosa; síndrome metabolico o síndrome X; síndrome de ovarios poliquísticos; adipogénesis y obesidad; miogénesis y debilidad, por ejemplo, la reduccion del rendimiento físico relacionado con la edad; sarcopenia aguda, por ejemplo, atrofia muscular y/o caquexia asociada con quemaduras, reposo en cama, inmovilizacion de miembros o cirugía torácica, abdominal y/u ortopédica mayor; sepsis; pérdida del cabello, debilitamiento del cabello y calvicie; e inmunodeficiencia.A compound to be of formula (1) in which: R1 is straight or branched chain C1-8 alkyl, straight or branched chain C2-8 alkenyl, C2-8 straight or branched chain alkynyl, C3-8 cycloalkyl, C4-8 cycloalkenyl, 3-8 membered heterocycloalkyl, C5-11 bicycloalkyl, C7-11 bicycloalkenyl, 5-11 membered heterobicycloalkyl, C6-14 aryl, or 5-14 membered heteroaryl; and R1 being optionally substituted with 1-6 R5 substituents independently selected from F, Cl, Br, I, nitro, cyano, -CF3, -NR7R8, -NR7C (= O) R8, -NR7C (= O) OR8, -NR7C (= O) NR8R, -NR7S (= O) 2R8, -NR7S (= O) 2R8R9, -OR7, -OC (= O) R7, -OC (= O) OR7, -C (= O) OR7, - C (= O) R7, -C (= O) NR7R8, -OC (= O) NR7R8, -OC (= O) SR7, -SR7, -S (= O) R7, -S (= O) 2R7, -S (= O) 2NR7R8, -OS (= O) 2R7, N3 and R7; R2 is H, F, -CH3, -CN or -C (= O) OR7; R3 is -C (= O) NR9, -C (= O) O-, -C (= O) (CR10R11) n-, or - (CR10R11) n-; R4 is C1-8 straight or branched chain alkyl, C2-8 straight or branched chain alkenyl, C2-8 straight or branched chain alkynyl, C3-8 cycloalkyl, C4-8 cycloalkenyl, 3-8 membered heterocycloalkyl, bicycloalkyl C5-11, C7-11 bicycloalkenyl, 5-11 membered heterobicycloalkyl, C6-14 aryl or 5-14 membered heteroaryl, R4 being optionally substituted with 1-3 R6 substituents independently selected from F, Cl, Br, I, nitro , cyano, -CF3, -NR7R8, -NR7C (= O) R8, -NR7C (= O) OR8, -NR7C (= O) NR8R9, -NR7S (= O) 2R8, -NR7S (= O) 2NR8R9, - OR7, -OC (= O) R7, -OC (= O) OR7, -C (= O) OR7, -C (= O) R7, -C (= O) NR7R8, -OC (= O) NR7R8, -OC (= O) SR7, -SR7, -S (= O) R7, -S (= O) 2R7, -S (= O) 2NR7R8, or R7; each of R7, R8 and R9 is independently selected from H, C1-8 straight or branched chain alkyl, C2-8 straight or branched chain alkenyl, C2-8 straight or branched chain alkynyl, C3-8 cycloalkyl, cycloalkenyl C4-8, 3-8 membered heterocycloalkyl, C5-11 bicycloalkyl, C7-11 bicycloalkenyl, 5-11 membered heterobicycloalkyl, C6-14 aryl and 5-14 membered heteroaryl, each being R7, R8 and R9 optional and independently substituted with 1-6 substituents selected from F, Cl, Br, I, NO2, -CN, -CF3, -NR10R11, -NR10C (= O) R11, -NR10C (= O) OR11, -NR10C (= O ) NR11R12, -NR10S (= O) 2R11, -NR10S (= O) 2NR11R12, -OR10, -OC (= O) R10, -OC (= O) OR10, -OC (= O) NR10R11, -OC (= O) SR10, -SR10, -S (= O) R10, -S (= O) 2R10, -S (= O) 2NR10R11, -C (= O) R10, -C (= O) OR10, -C ( = O) NR10R11 and R10; or, when R7 and R8 are as in NR7R8, they may be optionally linked to form, together with the NR7R8 nitrogen to which they are attached, a heterocycloalkyl moiety of 3-7 ring members, said heterocycloalkyl moiety optionally comprising 1-2 additional heteroatoms independently selected from N, O and S; each of R10, R11 and R12 is independently selected from H, C1-8 straight or branched chain alkyl, C2-8 straight or branched chain alkenyl, C2-8 straight or branched chain alkynyl, C3-8 cycloalkyl, cycloalkenyl C4-8, 3-8 membered heterocycloalkyl, C5-11 bicycloalkyl, C7-11 bicycloalkenyl, 5-11 membered heterobicycloalkyl, C6-14 aryl and 5-14 membered heteroaryl, each being R10, R11 and R12 optional and independently substituted with 1-6 substituents selected from F, Cl, Br, I, NO2, -CN, -CF3, -NR13R14, -NR13C (= O) R14, -NR13C (= O) OR14, -NR13C (= O ) NR14R15, -NR13S (= O) 2R14, -NR13S (= O) 2NR14R15, -OR13, -OC (= O) R13, -OC (= O) OR13, -OC (= O) NR13R14, -OC (= O) SR13, -SR13, -S (= O) R13, -S (= O) 2R13, -S (= O) 2NR13R14, -C (= O) R13, -C (= O) OR13, -C ( = O) NR13R14 and R13; each of R13, R14 and R15 is independently selected from H, C1-8 straight or branched chain alkyl, C2-8 straight or branched chain alkenyl, C2-8 straight or branched chain alkynyl, C3-8 cycloalkyl, cycloalkenyl C4-8, 3-8 membered heterocycloalkyl, C5-11 bicycloalkyl, C7-11 bicycloalkenyl, 5-11 membered heterobicycloalkyl, C6-14 aryl and 5-14 membered heteroaryl, each being R13, R14 and R15 optional and independently substituted with 1-6 substituents selected from F, Cl, Br, I, NO2, -CN, -CF3, -NR16R17, -NR16C (= O) R17, -NR16C (= O) OR17, -NR16C (= O ) NR17R18, -NR16S (= O) 2R17, -NR16S (= O) 2NR17R18, -OR16, -OC (= O) R16, -OC (= O) OR16, -OC (= O) NR16R17, -OC (= O) SR16, -SR16, -S (= O) R16, -S (= O) 2R16, -S (= O) 2NR16R17, -C (= O) R16, -C (= O) OR16, -C ( = O) NR16R17 and R16; each of R16, R17 and R18 is independently selected from H, C1-8 straight or branched chain alkyl, C2-8 straight or branched chain alkenyl, C2-8 straight or branched chain alkynyl, C3-8 cycloalkyl, cycloalkenyl C4-8, 3-8 membered heterocycloalkyl, C5-11 bicycloalkyl, C7-11 bicycloalkenyl, 5-11 membered heterobicycloalkyl, C6-13 aryl and 5-12 membered heteroaryl; n is 0, 1, 2 or 3; R10 and R11 being in -C (= O) (CR10R11) n- and - (CR10R11) n-, for each repetition of n, independently as mentioned above; or a pharmaceutically acceptable salt thereof. The compounds of formula (1) are indicated to have inhibitory activity of cdk5, cdk2 and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula (1) for treating and preventing diseases and conditions comprising abnormal cell growth, such as cancer, neurodegenerative diseases and conditions, and those affected by dopamine neurotransmission are also described. Pharmaceutical compositions and methods comprising compounds of formula (1) for treating male fertility and sperm motility are also described; Mellitus diabetes; decreased glucose tolerance; metabolic syndrome or syndrome X; polycystic ovarian syndrome; adipogenesis and obesity; myogenesis and weakness, for example, the reduction of age-related physical performance; acute sarcopenia, for example, muscular atrophy and / or cachexia associated with burns, bed rest, limb immobilization or thoracic, abdominal and / or major orthopedic surgery; sepsis; hair loss, hair weakening and baldness; and immunodeficiency.

ARP010103637A 2000-07-31 2001-07-30 COMPOUNDS DERIVED FROM IMIDAZOL AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AR032629A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22172400P 2000-07-31 2000-07-31

Publications (1)

Publication Number Publication Date
AR032629A1 true AR032629A1 (en) 2003-11-19

Family

ID=22829075

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103637A AR032629A1 (en) 2000-07-31 2001-07-30 COMPOUNDS DERIVED FROM IMIDAZOL AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM

Country Status (35)

Country Link
EP (1) EP1305295A1 (en)
JP (2) JP4166084B2 (en)
KR (1) KR20030019644A (en)
CN (1) CN1444567A (en)
AP (1) AP2001002232A0 (en)
AR (1) AR032629A1 (en)
AU (1) AU2001270944A1 (en)
BG (1) BG107469A (en)
BR (1) BR0112862A (en)
CA (1) CA2418115A1 (en)
CR (1) CR6861A (en)
CZ (1) CZ2003225A3 (en)
DO (1) DOP2001000220A (en)
EA (1) EA200300097A1 (en)
EC (1) ECSP034445A (en)
EE (1) EE200300049A (en)
GT (1) GT200100147A (en)
HR (1) HRP20030048A2 (en)
HU (1) HUP0303069A3 (en)
IL (1) IL153787A0 (en)
IS (1) IS6662A (en)
MA (1) MA26932A1 (en)
MX (1) MXPA03000939A (en)
NO (1) NO20030472L (en)
NZ (1) NZ523272A (en)
OA (1) OA12345A (en)
PA (1) PA8523701A1 (en)
PE (1) PE20020337A1 (en)
PL (1) PL365134A1 (en)
SK (1) SK1042003A3 (en)
SV (1) SV2002000571A (en)
TN (1) TNSN01114A1 (en)
UY (1) UY26862A1 (en)
WO (1) WO2002010141A1 (en)
ZA (1) ZA200300819B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
SI1478358T1 (en) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
CA2487948A1 (en) 2002-06-14 2003-12-24 Applied Research Systems Ars Holding N.V. Azole methylidene cyanide derivatives and their use as protein kinase modulators
US7141561B2 (en) 2002-07-25 2006-11-28 Sanofi-Aventis Deutschland Gmbh Substituted diaryl heterocycles, process for their preparation and their use as medicaments
DE10233817A1 (en) * 2002-07-25 2004-02-12 Aventis Pharma Deutschland Gmbh Substituted diaryl heterocycles, process for their preparation and their use as medicaments
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments
JP2007511203A (en) 2003-05-20 2007-05-10 バイエル、ファーマシューテイカルズ、コーポレイション Diarylurea with kinase inhibitory activity
SI1663978T1 (en) 2003-07-23 2008-02-29 Bayer Pharmaceuticals Corp Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
DE602005007717D1 (en) * 2004-03-23 2008-08-07 Pfizer Prod Inc IMIDAZOL COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2005110994A2 (en) 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Substituted pyrazolyl urea derivatives useful in the treatment of cancer
BRPI0515710A (en) 2004-09-21 2008-07-29 Astellas Pharma Inc amino alcohol compound, use of an amino alcohol compound, pharmaceutical composition and method for prophylactic and / or therapeutic treatment
US20080207594A1 (en) 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009508934A (en) * 2005-09-22 2009-03-05 ファイザー・プロダクツ・インク Imidazole compounds for the treatment of neurological disorders
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007084391A2 (en) 2006-01-18 2007-07-26 Amgen Inc. Thiazole compounds as protein kinase b ( pkb) inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
CN101573352A (en) 2006-10-21 2009-11-04 艾博特股份有限两合公司 Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
WO2009017453A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
US8455648B2 (en) * 2008-04-24 2013-06-04 Abbott Gmbh & Co. Kg 1-(7-(hexahydropyrrolo [3,4-c] pyrrol-2 (1H)-yl) quinolin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (GSK-3)
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9266855B2 (en) 2010-09-27 2016-02-23 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
PL2928474T3 (en) 2012-12-07 2019-05-31 Chemocentryx Inc Diazole lactams
PT2935227T (en) * 2012-12-21 2017-12-06 Chemocentryx Inc Diazole amides as ccr1 receptor antagonists
US10653672B2 (en) 2014-02-07 2020-05-19 National University Corporation Tokyo Medical And Dental University Myogenesis promotor, muscle atrophy inhibitor, medical composition and TAZ activator
WO2017040611A1 (en) 2015-08-31 2017-03-09 Nutramax Laboratories, Inc. Compositions comprising magnolia, phellodendron, theanine and/or whey protein
GB201605126D0 (en) * 2016-03-24 2016-05-11 Univ Nottingham Inhibitors and their uses
EP3439653B1 (en) 2016-04-07 2021-01-20 ChemoCentryx, Inc. Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
CN111018840B (en) * 2017-10-25 2022-09-09 西南大学 3-imidazole substituted isatin alcohol compound and preparation method and medical application thereof
EP3818044A1 (en) * 2018-07-03 2021-05-12 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
AU2020218366A1 (en) 2019-02-08 2021-09-16 Frequency Therapeutics, Inc. Valproic acid compounds and Wnt agonists for treating ear disorders
GB201908424D0 (en) * 2019-06-12 2019-07-24 Imp College Innovations Ltd Novel compounds
US10590087B1 (en) 2019-08-09 2020-03-17 Pfizer Inc. Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
US11884634B2 (en) 2019-08-09 2024-01-30 Pfizer Inc. Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
CN112250636A (en) * 2020-11-09 2021-01-22 广西科技大学 5-aminoimidazole compound and synthesis method thereof
MX2023013173A (en) 2021-05-07 2023-11-30 Kymera Therapeutics Inc Cdk2 degraders and uses thereof.
TW202328068A (en) 2021-09-01 2023-07-16 美商斯普林渥克斯治療有限公司 Synthesis of nirogacestat
US11504354B1 (en) 2021-09-08 2022-11-22 SpringWorks Therapeutics Inc.. Chlorinated tetralin compounds and pharmaceutical compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
US5760246A (en) * 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
ZA987383B (en) * 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
ZA987385B (en) * 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
DE69919707T2 (en) * 1998-06-19 2005-09-01 Chiron Corp., Emeryville GLYCOGEN SYNTHASE KINASE 3 INHIBITORS
WO2000021550A2 (en) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methods and compositions for treating neurodegenerative diseases
CO5160260A1 (en) * 1999-02-19 2002-05-30 Lilly Co Eli SECRETAGOGOS OF THE HORMONE OF GROWTH DERIVED FROM IMI- DAZOL 1,4- SUBSTITUTED
ES2213996T3 (en) * 1999-12-08 2004-09-01 Centre National De La Recherche Scientifique (Cnrs) USE OF HYMENIALDISINE OR ITS DERIVATIVES IN THE MANUFACTURE OF MEDICINES.

Also Published As

Publication number Publication date
PL365134A1 (en) 2004-12-27
SK1042003A3 (en) 2004-05-04
EP1305295A1 (en) 2003-05-02
ECSP034445A (en) 2003-03-10
WO2002010141A1 (en) 2002-02-07
CZ2003225A3 (en) 2004-02-18
JP2004505111A (en) 2004-02-19
EA200300097A1 (en) 2003-06-26
KR20030019644A (en) 2003-03-06
PE20020337A1 (en) 2002-05-08
JP4166084B2 (en) 2008-10-15
GT200100147A (en) 2002-06-25
UY26862A1 (en) 2002-02-28
CA2418115A1 (en) 2002-02-07
AP2001002232A0 (en) 2001-09-30
NZ523272A (en) 2004-08-27
TNSN01114A1 (en) 2005-11-10
JP2008255123A (en) 2008-10-23
BR0112862A (en) 2003-07-01
EE200300049A (en) 2004-10-15
BG107469A (en) 2003-09-30
IL153787A0 (en) 2003-07-31
MA26932A1 (en) 2004-12-20
CR6861A (en) 2004-03-11
HRP20030048A2 (en) 2003-04-30
NO20030472D0 (en) 2003-01-30
IS6662A (en) 2002-12-19
PA8523701A1 (en) 2002-04-25
MXPA03000939A (en) 2003-06-24
HUP0303069A2 (en) 2004-03-01
AU2001270944A1 (en) 2002-02-13
DOP2001000220A (en) 2002-05-15
SV2002000571A (en) 2002-10-24
CN1444567A (en) 2003-09-24
NO20030472L (en) 2003-03-27
OA12345A (en) 2004-04-13
ZA200300819B (en) 2004-04-20
HUP0303069A3 (en) 2004-04-28

Similar Documents

Publication Publication Date Title
AR032629A1 (en) COMPOUNDS DERIVED FROM IMIDAZOL AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM
AR035345A1 (en) COMPOUNDS DERIVED FROM PIRAZOL, PHARMACEUTICAL COMPOSITION, INTERMEDIARY COMPOUNDS
AR040031A1 (en) PIRAZOL-PYRIMIDINE ANILINE COMPOUNDS USED AS KINASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR067397A1 (en) TRIAZOL DERIVATIVES WITH ANTI-BANERIGAN ACTIVITY
AR041250A1 (en) SULFONAMIDE DERIVATIVES AS INHIBITORS OF TNF-ALFA CONVERTER ENZYMES
AR054625A1 (en) OXAZOLIDINONE COMPOUNDS, PROCEDURE TO PREPARE THEM, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND USE AS ANTIMICROBIAL AGENTS.
CO6260070A2 (en) CHEMICAL ENTITIES OF IMIDAZOPIRIDINE PAINS THE TREATMENT OF INFECTIONS WITH HEPATITIS C
CA2437524A1 (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
AR035436A1 (en) A BENZOPHENONE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE, SALTS, SALINE FORMS, PHARMACEUTICAL COMPOSITIONS, USES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, AND PROCESS FOR THE PREPARATION OF A BENZOPHENONE
AR037754A1 (en) HERBICIDES
AR064345A1 (en) 8-OXOADENINE DERIVATIVES
AR049124A1 (en) PIRIMIDINONE COMPOUNDS AS INHIBITORS OF THE INTEGRESS OF HIV VIRUS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF AIDS AND HIV INFECTION
AR019789A2 (en) COMPOUNDS DERIVED FROM ERYTHROMYCIN, COMPOSITIONS THAT CONTAIN THEM, USE OF THE SAME TO PREPARE A MEDICINAL PRODUCT
AR057979A1 (en) PIRAZOLPIRIMIDINAS AS INHIBITORS OF PROTEIN QUINASA. PHARMACEUTICAL COMPOSITIONS.
AR035087A1 (en) PIRIDIL-ALQUINOS AND PIRIDIL-N-OXIDO-ACTIVE HERBICIDE ALKINES, PROCEDURE FOR PREPARATION, HERBICIDE COMPOSITION AND TO INHIBIT THE GROWTH OF PLANTS, METHOD FOR CONTROLLING GROWTH OF INDESEABLE PLANTS, AND METHOD OF CREAM INHIBITION
CO5631447A2 (en) DERIVATIVES OF BENZOCONDESSED HETERIARILAMIDE OF USEFUL PIRIDINES AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE SAME, AND METHODS FOR USE
AR069637A1 (en) PIRAZINE DERIVATIVES
PE20070243A1 (en) HETEROCYCLIC COMPOUNDS AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE
ECSP099437A (en) HERBICIDE COMPOSITION
ES2572189T3 (en) 2,3-Dihydroimidazo [1,2-c] quinazoline substituted derivatives useful in the treatment of hyperproliferative disorders and diseases associated with angiogenesis
HUP0400266A2 (en) Pharmaceutical compositions containing imidazo[1,2-a]pyridine derivatives, and their use for the prophylaxis and treatment of herpes viral infections
NO20083520L (en) Tricyclic N-heteroaryl carboxamide derivatives containing a benzimidazole unit, process for the preparation of the same and their therapeutic uses
ES2570127T3 (en) Compounds and compositions as protein kinase inhibitors
AR072092A1 (en) DIAZACARBAZOLES AND METHODS OF USE
BRPI0707491B8 (en) compounds useful as mineralocorticoid receptor modulating agents, said agents comprising the same and pharmaceutical compositions

Legal Events

Date Code Title Description
FB Suspension of granting procedure